ImportantUpdates

Biocon Malaysia received EMA approval for its new insulin fill-finish unit.

Biocon Limited logo
Biocon LimitedBIOCON · Filed with the exchange

This expands manufacturing capacity for Semglee® (insulin glargine), enabling European market supplies to commence in Q2FY27.

Read the original filing(PDF)

No comments yet. Be the first.

More from Biocon Limited

All announcements